Liberty Capital Management Inc. Has $6.30 Million Stock Position in Abbott Laboratories $ABT

Key Points

• Liberty Capital Management Inc. increased its holdings in Abbott Laboratories by 5.5%, now owning approximately $6.30 million worth of shares.
• Recent insider activity saw CFO Philip P. Boudreau sell 5,550 shares for approximately $746,752.50, reducing his ownership by about 9.81%.
• Abbott Laboratories has announced a quarterly dividend of $0.59 per share, with an annualized yield of 1.8%, set to be paid on November 17th.

Liberty Capital Management Inc. lifted its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 5.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 46,340 shares of the healthcare product maker's stock after purchasing an additional 2,399 shares during the quarter. Abbott Laboratories accounts for 1.3% of Liberty Capital Management Inc.'s holdings, making the stock its 25th biggest holding. Liberty Capital Management Inc.'s holdings in Abbott Laboratories were worth $6,303,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Hughes Financial Services LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth $28,000. Elequin Capital LP acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth $30,000. JCIC Asset Management Inc. acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth $32,000. Finally, Vision Financial Markets LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth $33,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $133.97 on Wednesday. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $233.17 billion, a PE ratio of 16.79, a P/E/G ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The stock has a 50-day moving average price of $131.48 and a two-hundred day moving average price of $131.22.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same period last year, the company earned $1.14 earnings per share. The business's quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio (DPR) is 29.57%.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Evercore ISI raised their price objective on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Royal Bank Of Canada raised their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a research note on Tuesday, July 15th. William Blair raised Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Jefferies Financial Group raised Abbott Laboratories from a "hold" rating to a "buy" rating and raised their price objective for the company from $143.00 to $145.00 in a research note on Friday, July 18th. Finally, Raymond James Financial reduced their price objective on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a research note on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $145.22.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.